Terms: = Pancreatic cancer AND Ki-67 AND Clinical Outcome
16 results:
1. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
[TBL] [Abstract] [Full Text] [Related]
2. Anti-Allergic Drug Suppressed pancreatic Carcinogenesis via Down-Regulation of Cellular Proliferation.
Kachi K; Kato H; Naiki-Ito A; Komura M; Nagano-Matsuo A; Naitoh I; Hayashi K; Kataoka H; Inaguma S; Takahashi S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299067
[TBL] [Abstract] [Full Text] [Related]
3. Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm.
Cavalcoli F; Pusceddu S; Zilli A; Tamagno G; Femia D; Prinzi N; Travers J; Consonni D; Ciafardini C; Conte D; Massironi S
Scand J Gastroenterol; 2019 Sep; 54(9):1111-1117. PubMed ID: 31454281
[No Abstract] [Full Text] [Related]
4. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
[TBL] [Abstract] [Full Text] [Related]
6. pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of ki-67 in solid pseudopapillary tumor of the pancreas: Huashan experience and systematic review of the literature.
Yang F; Yu X; Bao Y; Du Z; Jin C; Fu D
Surgery; 2016 Apr; 159(4):1023-31. PubMed ID: 26619927
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of Three ki-67 Index Quantification Methods and clinical Significance in pancreatic Neuroendocrine Tumors.
Kroneman TN; Voss JS; Lohse CM; Wu TT; Smyrk TC; Zhang L
Endocr Pathol; 2015 Sep; 26(3):255-62. PubMed ID: 26072124
[TBL] [Abstract] [Full Text] [Related]
9. Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome.
Kim JC; Kim KT; Park JT; Kim HJ; Sato Y; Kim HS
Hepatogastroenterology; 2015; 62(138):251-6. PubMed ID: 25916042
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract] [Full Text] [Related]
11. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
[TBL] [Abstract] [Full Text] [Related]
12. Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis.
Ohike N; Morohoshi T
Endocr Pathol; 2005; 16(1):33-40. PubMed ID: 16000844
[TBL] [Abstract] [Full Text] [Related]
13. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis.
Nakopoulou L; Giannopoulou I; Stefanaki K; Panayotopoulou E; Tsirmpa I; Alexandrou P; Mavrommatis J; Katsarou S; Davaris P
J Pathol; 2002 Jul; 197(3):307-13. PubMed ID: 12115876
[TBL] [Abstract] [Full Text] [Related]
14. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors.
Gentil Perret A; Mosnier JF; Buono JP; Berthelot P; Chipponi J; Balique JG; Cuilleret J; Dechelotte P; Boucheron S
Am J Clin Pathol; 1998 Mar; 109(3):286-93. PubMed ID: 9495200
[TBL] [Abstract] [Full Text] [Related]
15. High-affinity monomeric 67-kD laminin receptors and prognosis in pancreatic endocrine tumours.
Pelosi G; Pasini F; Bresaola E; Bogina G; Pederzoli P; Biolo S; Menard S; Zamboni G
J Pathol; 1997 Sep; 183(1):62-9. PubMed ID: 9370949
[TBL] [Abstract] [Full Text] [Related]
16. Expression of ki-67 by monoclonal antibody MIB-1 in carcinoma of the middle and lower bile duct.
Yamada Y; Yamauchi H; Kakizaki K; Suzuki H
Tohoku J Exp Med; 1995 Dec; 177(4):375-7. PubMed ID: 8928197
[TBL] [Abstract] [Full Text] [Related]
